We develop and manufacture diverse cell therapies including CD34+ hematopoietic stem cells, autologous and allogenic T-cells, and NK cells. Our cell therapy capabilities cover numerous technologies, ranging from closed to open systems at different scales, depending on client needs. We also develop and manufacture adeno-associated viral vectors, lenti viral vectors and retro viral vectors. Our ready-to-use platform capabilities are built on cell factories (up to 48L) and bioreactors (up to 200L) using adherent processes, designed entirely in-house.
The 7th Annual CAR-TCR Summit is back, bigger and better than ever, uniting experts with one common goal: engineering a disease-free world.
Gain end-to-end insights from both established thought leaders and the innovators bringing disruptive technologies from bench to bedside and from vein to vein.
Across 3 conference days with 8 tracks, 15 Workshops, 1 Bootcamp and 1 Focus Day, 200+ CAR and TCR experts will lead you and 1,000 of your peers in discussions that will accelerate your pipeline and bring much-needed treatments to patients faster.